Digital directly observed therapy to monitor adherence to medications: a scoping review

References

• Liu AY, Laborde ND, Coleman K, et al. DOT diary: developing a novel mobile app using artificial intelligence and an electronic sexual diary to measure and support PrEP adherence among young men who have sex with men. AIDS Behav. 2021;25(4):1001–1012.
   Web of Science ®Google Scholar
• MaCaraig M, Lobato MN, McGinnis Pilote K, Wegener D. A national survey on the use of electronic directly observed therapy for treatment of tuberculosis. J Public Heal Manag Pract. 2018;
   Web of Science ®Google Scholar
• Garfein RS, Doshi RP. Synchronous and asynchronous video observed therapy (VOT) for tuberculosis treatment adherence monitoring and support. J Clin Tuberc Other Mycobact Dis. 2019;17:100098.
   PubMedGoogle Scholar
• Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51(1):1701596.
   Web of Science ®Google Scholar
• Parmar P, Mackie D, Varghese S, Cooper C. Use of telemedicine technologies in the management of infectious diseases: a review. Clin Infect Dis. 2015;
   Google Scholar
• Saberi P, Yuan P, John M, Sheon N, Johnson MO. A Pilot Study to Engage and Counsel HIV-Positive African American Youth Via Telehealth Technology. AIDS Patient Care STDS. 2013;27(9):529–532.
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2014;
   Web of Science ®Google Scholar
• Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-Infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–537.
   PubMed Web of Science ®Google Scholar
• Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
   PubMed Web of Science ®Google Scholar
• Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–187.
   PubMed Web of Science ®Google Scholar
• Paolillo EW, Gongvatana A, Umlauf A, Letendre SL, Moore DJ. At-risk alcohol use is associated with antiretroviral treatment nonadherence among adults living with HIV/AIDS. Alcohol Clin Exp Res. 2017;41(8):1518–1525.
   PubMed Web of Science ®Google Scholar
• Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8(4):277–287.
   PubMedGoogle Scholar
• Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital signs: HIV transmission along the continuum of care—United States, 2016. MMWR Morb Mortal Wkly Rep. 2019;68(11):267–272.
   PubMed Web of Science ®Google Scholar
• Chesney MA. The elusive gold standard. JAIDS J Acquir Immune Defic Syndr. 2006;43(Supplement 1):S149–S155.
   Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183.
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385–394.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–347.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor–based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564.
   PubMed Web of Science ®Google Scholar
• Crepaz N, Dong X, Hess KL, Bosh K. Brief report: racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons aged 13-29 years living with diagnosed HIV infection, United States, 2016. J Acquir Immune Defic Syndr. 2020;83(4):334–339.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
   PubMed Web of Science ®Google Scholar
• Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, VOICE Study Team, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Pre-Exposure Prophylaxis (PrEP). https://www.cdc.gov/hiv/risk/prep/index.html. Accessed February 1, 2018.
   Google Scholar
• CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: A Clinical Practice Guideline. Atlanta, Georgia; 2014. www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. 107326/M18-0850.
   PubMed Web of Science ®Google Scholar
• Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke 2017;48(5):1416–1419.
   PubMed Web of Science ®Google Scholar
• Veritas Health Innovation. Covidence systematic review sofware. Covidence. www.covidence.org %0A–0A. Published; 2019.
   Google Scholar
• Shields MD, ALQahtani F, Rivey MP, McElnay JC. Mobile direct observation of therapy (MDOT): a rapid systematic review and pilot study in children with asthma. PLoS ONE. 2018;13(2):e0190031.
   PubMed Web of Science ®Google Scholar
• Holzman SB, Atre S, Sahasrabudhe T, et al. Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study. JMIR Form Res. 2019;3(3):e13411.
   PubMedGoogle Scholar
• Sekandi JN, Buregyeya E, Zalwango S, et al. Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Res. 2020;6(1):00175–2019–02019.
   PubMedGoogle Scholar
• Nguyen TA, Pham MT, Nguyen TL, et al. Video directly observed therapy to support adherence with treatment for tuberculosis in Vietnam: a prospective cohort study. Int J Infect Dis. 2017;65:85–89.
   Web of Science ®Google Scholar
• Molton JS, Pang Y, Wang Z, et al. Prospective single-arm interventional pilot study to assess a smartphone-based system for measuring and supporting adherence to medication. BMJ Open. 2016;6(12):e014194.
   PubMed Web of Science ®Google Scholar
• Godersky ME, Klein JW, Merrill JO, et al. Acceptability and feasibility of a mobile health application for video directly observed therapy of buprenorphine for opioid use disorders in an office-based setting. 2020.
   Google Scholar
• Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet 2019;393(10177):1216–1224.
   PubMed Web of Science ®Google Scholar
• Guo X, Yang Y, Takiff HE, et al. A comprehensive app that improves tuberculosis treatment management through video-observed therapy: usability study. JMIR Mhealth Uhealth. 2020;8(7):e17658.
   Web of Science ®Google Scholar
• Holzman SB, Zenilman A, Shah M. Advancing patient-centered care in tuberculosis management: a mixed-methods appraisal of video directly observed therapy. Open Forum Infect Dis. 2018;5(4):ofy046.
   PubMed Web of Science ®Google Scholar
• Garfein RS, Collins K, Muñoz F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis. 2015;19(9):1057–1064.
   PubMed Web of Science ®Google Scholar
• Hoffman JA, Cunningham JR, Suleh AJ, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med. 2010;39(1):78–80.
   PubMed Web of Science ®Google Scholar
• Olano-Soler H, Thomas D, Joglar O, et al. Notes from the field: use of asynchronous video directly observed therapy for treatment of tuberculosis and latent tuberculosis infection in a long-term–care facility―Puerto Rico, 2016–2017. MMWR Morb Mortal Wkly Rep. 2017;66(50):1386–1387.
   Web of Science ®Google Scholar
• Sinkou H, Hurevich H, Rusovich V, et al. Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience. Eur Respir J. 2017;49(3):1602049.
   PubMed Web of Science ®Google Scholar
• Lam CK, Pilote KMG, Haque A, Burzynski J, Chuck C, Macaraig M. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study. J Med Internet Res. 2018;20(11):e287.
   Web of Science ®Google Scholar
• Buchman T, Cabello C. A New Method to Directly Observe Tuberculosis Treatment: Skype Observed Therapy, a Patient-Centered Approach. 2017;
   Google Scholar
• Bendiksen R, Ovesen T, Asfeldt AM, Halvorsen DS, Gravningen K. Use of video directly observed treatment for tuberculosis in Northern Norway. Tidsskr Den nor Laegeforening. 2020;140(1)
   Web of Science ®Google Scholar
• Donahue ML, Eberly MD, Rajnik M. Tele-TB: using telemedicine to increase access to directly observed therapy for latent tuberculosis infection. Mil Med. 2021;186(Suppl 1):25–31.
   Google Scholar
• Guo P, Qiao W, Sun Y, Liu F, Wang C. Telemedicine technologies and tuberculosis management: a randomized controlled trial. Telemed. e-Health 2020;26(9):1150–1156.
   Google Scholar
• Chen SH, Wang I, Hsu HL, et al. Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection. J Infect Public Health. 2020;13(9):1354–1359.
   Web of Science ®Google Scholar
• DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis. 2001;33(12):2082–2084.
   PubMed Web of Science ®Google Scholar
• Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int j Tuberc Lung Dis. 2016;20(5):588–593.
   PubMed Web of Science ®Google Scholar
• Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One. 2012;7(11):e50155.
   Web of Science ®Google Scholar
• Mirsaeidi M, Farshidpour M, Banks-Tripp D, Hashmi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. Eur Respir J. 2015;46(3):871–874.
   PubMed Web of Science ®Google Scholar
• Holzschuh EL, Province S, Johnson K, et al. Use of video directly observed therapy for treatment of latent tuberculosis infection—Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(14):387–389.
   Web of Science ®Google Scholar
• Cole SR, Hudgens MG. Survival analysis in infectious disease research: describing events in time. AIDS. 2010;24(16):2423–2431.
   PubMed Web of Science ®Google Scholar
• Bain EE, Shafner L, Walling DP, et al. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a phase 2 clinical trial in subjects with schizophrenia. JMIR Mhealth Uhealth. 2017;5(2):e18.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Skinner D, Jennings L, et al. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Prefer Adherence. 2016;10:683–690.
   PubMed Web of Science ®Google Scholar
• Himelhoch S, Kreyenbuhl J, Palmer-Bacon J, Chu M, Brown C, Potts W. Pilot feasibility study of Heart2HAART: a smartphone application to assist with adherence among substance users living with HIV. AIDS Care. 2017;29(7):898–904.
   PubMed Web of Science ®Google Scholar
• Lee M, Lee H, Kim Y, et al. Mobile app-based health promotion programs: a systematic review of the literature. IJERPH. 2018;15(12):2838.
   Google Scholar
• Gold J, Lim MSC, Hocking JS, Keogh LA, Spelman T, Hellard ME. Determining the impact of text messaging for sexual health promotion to young people. Sex Transm Dis. 2011;
   Web of Science ®Google Scholar
• Mulawa MI, LeGrand S, Hightow-Weidman LB. eHealth to enhance treatment adherence among youth living with HIV. Curr HIV/AIDS Rep. 2018;15(4):336–349.
   PubMed Web of Science ®Google Scholar
• Hoots BE, Finlayson TJ, Wejnert C, Paz-Bailey G, NHBS Study Group Early linkage to hiv care and antiretroviral treatment among men who have sex with men—20 cities, United States, 2008 and 2011. PLoS One. 2015;10(7):e0132962.
   Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684–691.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Milloy M-J, Kerr T, et al. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDS. 2012;26(5):274–280.
   PubMed Web of Science ®Google Scholar
• Martinez J, Harper G, Carleton RA, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care. AIDS Patient Care STDS. 2012;26(2):108–115.
   PubMed Web of Science ®Google Scholar
• Marks G, Gardner LI, Rose CE, et al. Time above 1500 copies. AIDS. 2015;29(8):947–954.
   PubMed Web of Science ®Google Scholar
• Demographics of Mobile Device Ownership and Adoption in the United States | Pew Research Center. https://www.pewresearch.org/internet/fact-sheet/mobile/. Accessed April 2, 2021.
   Google Scholar
• Saberi P. Research in the time of coronavirus: continuing ongoing studies in the midst of the COVID-19 pandemic. AIDS Behav. 2020;24(8):2232–2235.
   PubMed Web of Science ®Google Scholar